San Diego, September 5, 2023 – Inmagene Biopharmaceuticals, a trailblazing clinical-stage biotech firm dedicated to pioneering therapies for immunological and inflammatory diseases, has just scored a remarkable addition to its leadership team. They proudly announce the appointment of David Topper as their new Chief Financial Officer (CFO).
With an illustrious career spanning nearly four decades, David brings a wealth of financial expertise, investment management acumen, and a sterling track record in investment banking to the Inmagene family. His previous roles include a distinguished partnership at Frazier Life Sciences, a heavyweight in the investment management sector overseeing approximately $5 billion in assets.
Notably, he also served as the CFO and a board director of Frazier Life Sciences Acquisition Corporation, a company that orchestrated a highly successful merger with New Amsterdam Pharma, with David playing a pivotal role in this achievement.
David’s journey in finance took him to General Atlantic Partners, a growth equity investment powerhouse managing around $35 billion. Prior to that, he made a mark at J.P. Morgan as Co-Head of Equity Capital Markets and Chairman of the Commitments Committee. His tenure of 22 years at Morgan Stanley was equally impressive, where he held key roles, including Co-Head of Equity Capital Markets, Managing Director, and Chairman of the Commitments Committee.
Beyond his professional exploits, David has shared his insights by serving on the boards of numerous prominent companies. His commitment to education and culture shines through his involvement with the Duke University Trinity School of Arts and Sciences, The Jewish Museum of New York, and the Adams Memorial Foundation.
David’s educational journey speaks to his excellence, having earned his B.A. from Duke University and an M.B.A. from the prestigious Stanford University.
In welcoming David, Jonathan Wang, Ph.D., Chief Executive Officer of Inmagene, expressed immense enthusiasm. He believes that David’s unparalleled expertise in finance, investment management, and capital markets, coupled with his deep-rooted biotech industry experience, will play a pivotal role in driving Inmagene’s growth and strategic endeavors.
David Topper himself shared his excitement about joining Inmagene, emphasizing the company’s multiple clinical-stage assets, promising data, and unwavering focus on the fields of immunology and inflammation. He underscored the exceptional management team and the strong shareholder base as factors that make this opportunity truly thrilling. David is eager to contribute to Inmagene’s financial and capital market objectives as they continue their journey towards transformative breakthroughs in healthcare.
Meet Inmagene, a global clinical-stage biotech powerhouse dedicated to pioneering groundbreaking therapies for the world’s most challenging immunological and inflammatory diseases. This dynamic firm boasts not one but four clinical-stage drug candidates, each a potential game-changer in its own right.
At the forefront stands IMG-007, a lead compound with awe-inspiring potential. As an OX40 antagonist mAb, it comes armed with an extended half-life and a silenced ADCC function, setting it apart in the race to combat debilitating diseases. Currently, it’s blazing a trail in two global POC clinical trials, poised to redefine treatment standards.
IMG-004 is another star in Inmagene’s constellation—a non-covalent, reversible Bruton’s tyrosine kinase (BTK) inhibitor. What makes it extraordinary? Its ability to deliver a more durable pharmacodynamic effect and a longer half-life than most, if not all, leading BTK inhibitors. With Phase 1 clinical development nearly wrapped up, IMG-004 is ready to take its place in the spotlight.
But the innovation doesn’t stop there. Enter IMG-008, a long-acting mAb targeting IL-36R. With an extended half-life and enhanced antibody exposure compared to an approved IL-36R antagonist, it’s poised to usher in a new era of treatment. Currently, it’s gearing up for global Phase 1 clinical development.
And that’s not all—IMG-020, also known as izokibep, is making waves as an anti-IL-17 small protein therapeutic. It’s not just limited to one arena; it’s in global clinical development for five indications, with two pivotal trials in collaboration with global partners. This versatile contender is all set to redefine healthcare solutions.
Fueling Inmagene’s innovation is its proprietary QuadraTek® platform—a breeding ground for novel drug candidates that hold the promise of transforming lives. But innovation doesn’t happen in isolation; Inmagene is all about partnerships. They’ve forged strategic alliances with powerhouses like HUTCHMED and Affibody AB to collectively drive the development of highly innovative drug candidates.
Inmagene isn’t just pushing boundaries; they’re reshaping the future of healthcare—one breakthrough at a time.